GLP-1 Pills (2026): Rybelsus, Foundayo & the New Wegovy Tablet — Side-by-Side Comparison of Every Oral GLP-1

Three oral GLP-1 medications matter for US patients in 2026, and — as of a June 2026 label update — all three are now FDA-approved: Rybelsus (oral semaglutide, Novo Nordisk — FDA-approved 2019, type 2 diabetes only), Foundayo (oral orforglipron, Eli Lilly — FDA-approved April 1, 2026, for chronic weight management), and Wegovy tablets (high-dose oral semaglutide, Novo Nordisk — added to the Wegovy label in 2026, for cardiovascular risk reduction or weight reduction in adults). Wegovy tablets are a genuinely new product, not a Rybelsus relabel: they use 1.5/4/9/25 mg strengths (Rybelsus uses 3/7/14/25 mg) and share the WEGOVY brand and SetID with the original injection. All three are once-daily, but their dosing strictness, food restrictions, indications, formulations, effect sizes, and prices differ materially — anchored to the verbatim DailyMed labels (Rybelsus SetID 27f15fac-7d98-4114-a2ec-92494a91da98; Foundayo SetID 8ac446c5-feba-474f-a103-23facb9b5c62; Wegovy SetID ee06186f-2aa3-4990-a760-757579d8f77b, SPL v19, Jun 30 2026) and the verified PIONEER^[3], ATTAIN-1^[5], and OASIS-4^[11] trials.

What “GLP-1 pill” actually means in 2026

The injectable GLP-1 receptor agonists — Wegovy (semaglutide), Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide), Saxenda and Victoza (liraglutide), Trulicity (dulaglutide) — dominate the class by prescription volume. For the full FDA-approved-and-investigational drug list see our GLP-1 medication list 2026 full reference . But every one of them requires a needle, refrigeration, and weekly injection technique. The oral GLP-1 category — daily pill, no injection, no refrigerator — has long been a patient priority and a regulatory target. As of a June 2026 label update there are three FDA-approved oral GLP-1 receptor agonists :

• Rybelsus (oral semaglutide, Novo Nordisk) — peptide GLP-1 with the SNAC absorption enhancer. FDA-approved September 2019. Indication: type 2 diabetes only.
• Foundayo (oral orforglipron, Eli Lilly) — non-peptide small-molecule GLP-1 receptor agonist. FDA-approved April 1, 2026. Indication: chronic weight management.

A third product now belongs in this comparison: Novo Nordisk's Wegovy tablets — high-dose oral semaglutide, at approved strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg, added to the Wegovy FDA label in 2026 following the OASIS-4 trial (Study 7, NCT05564117, published as Wharton 2025 NEJM^[11]). The semaglutide molecule is shared with Rybelsus, but Rybelsus is approved at different strengths (3 / 7 / 14 / 25 mg) and only for type 2 diabetes — Wegovy tablets are approved for cardiovascular risk reduction or weight reduction in adults, the same indications as the Wegovy injection, and share its SetID and brand. Patients should verify the specific product and indication on the dispensed prescription label — "oral semaglutide" alone does not tell you which of the two distinct brands (Rybelsus or Wegovy tablets) or which indication applies.

The GLP-1 receptor agonist class extends further — the Trulicity molecule and oral DPP-4 inhibitors (sitagliptin, linagliptin) are sometimes confused with oral GLP-1s. They are not. Trulicity is an injectable Fc-fusion biologic (BLA pathway, see our Trulicity weight-loss evidence review ); DPP-4 inhibitors raise endogenous GLP-1 weakly and are not GLP-1 receptor agonists. This article is restricted to the two FDA-approved oral GLP-1 receptor agonists plus the explicit not-approved status of high-dose oral semaglutide for weight management.

Side-by-side comparison: every oral GLP-1

The headline differences in one table — every cell anchored to a primary-source FDA label or to a verified PMID, with cross-trial caveats called out in the deep-dive sections below.

Two cells deserve immediate amplification because they are the most frequent patient-question gaps:

• Rybelsus is NOT approved for weight loss. Patients prescribed Rybelsus by a primary-care clinician for weight management are receiving the medication off-label for that purpose. Insurance coverage for Rybelsus is structured around its T2D indication.
• Wegovy tablets and the Wegovy injection are both FDA-approved for weight reduction — as of the 2026 label update, patients have a real choice between the injectable Wegovy pen (2.4 mg weekly, or 7.2 mg “Wegovy HD”) and the Wegovy tablet (25 mg once daily). They are not interchangeable without a prescriber-guided switch (see the label’s dedicated switching instructions).

Rybelsus deep-dive (oral semaglutide)

Rybelsus was the first FDA-approved oral GLP-1 receptor agonist (September 2019), and remains the only oral semaglutide product on the US market. The semaglutide molecule is identical to Ozempic (subcutaneous, T2D) and Wegovy (subcutaneous, weight management). What makes Rybelsus unique — and what creates its demanding administration regimen — is the SNAC absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently protects the semaglutide peptide from gastric pH and proteolysis long enough for absorption across the stomach epithelium. Even with SNAC, the bioavailability is on the order of 1% — meaning oral doses are roughly two orders of magnitude higher than bioequivalent subcutaneous doses (3-25 mg PO vs 0.25-2.4 mg SC).

Indication and dosing — verbatim

Per §1 INDICATIONS AND USAGE of the Rybelsus DailyMed label (SetID 27f15fac-7d98-4114-a2ec-92494a91da98), Rybelsus is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease — added October 2025 per the SOUL trial (7 mg + 14 mg only)

Rybelsus is NOT FDA-approved for chronic weight management . Patients seeking weight loss are not the labeled population. Off-label prescribing for weight loss occurs but is not the cleaner path; the weight-management-indicated brands (Wegovy, Zepbound, Foundayo, Saxenda) are.

Per §2 DOSAGE AND ADMINISTRATION, the dosing ladder is:

• 3 mg orally once daily for 30 days (a starting / acclimation dose; not therapeutic)
• 7 mg orally once daily after the 30-day starting dose
• 14 mg orally once daily, after at least 30 days on 7 mg, if additional glycemic control is needed
• 25 mg orally once daily — added per recent label expansion in some markets; 25 mg is not yet universally listed in every Rybelsus PI revision

The Rybelsus food restriction (verbatim — strict, material, load-bearing)

The single most important practical fact about Rybelsus is the §2 administration rule. From the verbatim DailyMed label:

“Take RYBELSUS at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water only. Taking with more than 4 ounces of water, with food, or with other oral medications will reduce semaglutide absorption.”

This is the strictest administration rule in the entire GLP-1 class. Practical implications most patients underestimate:

• Coffee, tea, juice, milk, electrolyte drinks, or any other beverage in the morning will reduce absorption. Plain water only — and no more than 4 ounces. The Rybelsus PI explicitly does not waive this for any beverage.
• Other morning medications (statins, SSRIs, levothyroxine, blood pressure pills, oral contraceptives) cannot be taken in the same window. Rybelsus must be the first thing in the day; the 30-minute wait must elapse before any other oral medication.
• Breakfast must wait at least 30 minutes after the dose. Some patients extend this to 45-60 minutes for safety margin; the label minimum is 30. A patient who routinely eats within 15-20 minutes of the dose is materially underdosed.
• Weekend / travel mornings are the highest-risk failure point. Patients who skip the dose because they want coffee immediately — or take it inconsistently because the fasted-morning routine breaks on weekends — see reduced steady-state concentrations and reduced glycemic effect.

The food restriction is mechanistic: the SNAC enhancer creates a brief absorption window in the stomach that is defeated by gastric distension, food, or fluid volume. Patients who tell their prescriber “I take Rybelsus with my coffee” are taking a much-reduced effective dose.

Trial efficacy — PIONEER program

Rybelsus was developed through the PIONEER (Peptide Innovation for Early Diabetes Treatment) Phase 3 program. The trials measured HbA1c reduction and CV outcomes — not weight loss as a primary endpoint. Two anchor publications:

• PIONEER 3 (Rosenstock et al., JAMA 2019, PMID 30903796 ): 78-week T2D trial showing oral semaglutide 7 mg and 14 mg produced significantly greater HbA1c reduction than sitagliptin 100 mg, with body-weight reductions of 2.7 kg (7 mg) and 4.5 kg (14 mg) at week 26 — modest weight effect relative to subcutaneous semaglutide at the same molecular dose-equivalent.
• PIONEER 6 (Husain et al., NEJM 2019, PMID 31185157 ): Cardiovascular safety trial of oral semaglutide vs placebo in T2D patients at high CV risk. The composite MACE endpoint occurred in 3.8% (semaglutide) vs 4.8% (placebo) over a median 15.9 months — non-inferior for safety. This trial established the foundation that supported the October 2025 CV-risk-reduction indication added to the Rybelsus label (limited to 7 mg + 14 mg, per the SOUL trial as well).

Notably absent from the Rybelsus trial program: a weight-management Phase 3 trial. Novo Nordisk pursued the weight-management indication for oral semaglutide separately — at higher doses (25 / 50 mg) under the OASIS program — which is the candidate sometimes called “Wegovy oral” (covered below).

Foundayo deep-dive (oral orforglipron)

Foundayo received FDA approval on April 1, 2026 — the first oral GLP-1 receptor agonist FDA-approved for chronic weight management, and the first non-peptide small-molecule GLP-1 RA in the entire class. Eli Lilly developed orforglipron specifically to bypass the peptide-stability problem that forces Rybelsus into its strict fasted-morning regimen. Because orforglipron is a small organic molecule (not a peptide), it survives gastric pH, requires no absorption enhancer, and has no food-restriction requirement. The clinical and practical consequences are large.

Indication and dosing — verbatim

Per §1 INDICATIONS AND USAGE of the Foundayo DailyMed label (SetID 8ac446c5-feba-474f-a103-23facb9b5c62), Foundayo is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbid condition. Foundayo is not FDA-approved for type 2 diabetes glycemic control as of May 2026 (the ATTAIN-2 T2D + obesity trial supports the molecule's glycemic effect, but the T2D indication has not yet been added to the label).

Per §2 DOSAGE AND ADMINISTRATION, the dosing ladder is:

“The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily. The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

Six discrete dose strengths, each ≥30 days. The minimum time-to-top-dose is approximately 5 months. For the full calendar walk-through see our Foundayo week-by-week titration guide .

Foundayo food rule (verbatim) — the contrast with Rybelsus

Per §2 of the Foundayo label, verbatim:

“Take FOUNDAYO orally once daily, with or without food.”

That single sentence is the largest practical advantage of Foundayo over Rybelsus for many patients. There is no fasted morning window, no 4-ounce water cap, no 30-minute pre-food wait, no pre-medication sequencing constraint. Patients can take Foundayo with coffee, with breakfast, with their morning blood-pressure pill, with a glass of orange juice — none of those reduce absorption. The label adds two administration constraints, both verbatim:

• “Swallow tablets whole. Do not break, crush, or chew.”
• “Do not take more than one tablet per day.”

Trial efficacy — ATTAIN program

The Foundayo Phase 3 program — ATTAIN — produced two anchor publications by April 2026:

• ATTAIN-1 (Wharton et al., NEJM 2025, PMID 40960239 ): 72-week trial in adults with obesity or overweight (without T2D). Per §14 CLINICAL STUDIES of the DailyMed label, orforglipron 17.2 mg produced −11.1% body weight vs −2.1% placebo (Δ −9.0%) at 72 weeks; 9 mg produced −8.3%; 5.5 mg produced −7.4%. Baseline weight 103.9 kg.
• ATTAIN-2 (Horn et al., Lancet 2026, PMID 41275875 ): 72-week trial in adults with obesity or overweight plus type 2 diabetes. Demonstrated weight loss and HbA1c reduction. Has not yet been used to add a T2D indication to the Foundayo label as of May 2026.

These are the primary published Phase 3 weight-loss-as-primary-endpoint trials for Foundayo. PIONEER (Rybelsus) measured HbA1c, not weight loss as a primary endpoint. The parallel OASIS program (high-dose oral semaglutide) is covered in the next section — its weight-management formulation, now sold as Wegovy tablets, was FDA-approved in 2026.

Wegovy tablets: approved in 2026, alongside the injection

The OASIS Phase 3 program — Novo Nordisk's weight-management trial program for high-dose oral semaglutide — tested doses of 1.5 mg, 4 mg, 25 mg, and 50 mg across several trials. OASIS-1 (published 2023) showed oral semaglutide 50 mg produced approximately 15.1% body-weight reduction at 68 weeks vs placebo. The pivotal trial behind the actual FDA approval, however, is OASIS-4 / Study 7 (NCT05564117, Wharton 2025 NEJM^[11]), a 64-week trial of the lower, approved 25 mg maintenance dose: WEGOVY 25 mg tablets produced −13.6% body weight (LSMean) vs −2.4% with placebo, a −11.2% treatment difference (95% CI −13.6 to −8.8, p<0.0001), with 76.3% of tablet-treated patients losing at least 5% of body weight vs 31.3% on placebo. The FDA approved the 25 mg maintenance dose, not the higher 50 mg dose tested in earlier OASIS trials. The weight-management semaglutide products now on the US market are the injectable Wegovy pen (subcutaneous, 2.4 mg or the 7.2 mg “Wegovy HD”) and, since the 2026 label update, the Wegovy 25 mg tablet.

Cross-comparison: which oral GLP-1 produces the most weight loss?

This question requires immediate caveats. There is no head-to-head trial comparing Rybelsus to Foundayo, or Foundayo to high-dose oral semaglutide. Cross-trial comparisons rest on different patient populations, different baseline weights, different durations, different placebo run-ins, and different adherence profiles. With those caveats, the best available trial-anchored weight-loss numbers for each oral agent:

Read carefully:

• The Wegovy 25 mg tablet (OASIS-4, −13.6% at 64 weeks) now carries the largest FDA-approved oral GLP-1 weight-loss claim, ahead of Foundayo 17.2 mg (ATTAIN-1, −11.1% at 72 weeks) — though the two trials differ in duration and population, so treat the ranking as directional, not a head-to-head result.
• Rybelsus weight-loss numbers are from T2D trials, not weight-management trials. Patients on Rybelsus generally see modest weight loss as a secondary effect, but the trial program never targeted the weight-management indication and the population was T2D- enriched (different baseline metabolic profile).
• High-dose oral semaglutide 50 mg in the earlier OASIS-1 trial produced larger numerical weight loss than the approved products — but the FDA ultimately approved a lower 25 mg maintenance dose (OASIS-4/Study 7, −13.6%), not 50 mg, so 50 mg is not an approved dose and its trial result is not directly comparable to what patients can actually be prescribed.
• For context vs injectable GLP-1s: Wegovy 2.4 mg (subcutaneous) produced ~−14.9% in STEP-1 over 68 weeks; Zepbound 15 mg (subcutaneous) produced ~−20.9% in SURMOUNT-1 over 72 weeks. Even including the new Wegovy 25 mg tablet (−13.6% in OASIS-4^[11]), the injectables still produce greater weight loss than any FDA-approved oral GLP-1 today.

The indication mismatch: Rybelsus is T2D-only

Patients regularly conflate “oral semaglutide” with “oral Wegovy.” As of the 2026 label update, “oral Wegovy” is a real, specific product (the Wegovy tablet) — but it is still a different product from Rybelsus, even though both are oral semaglutide. Semaglutide is the molecule; Wegovy (injection and tablet), Ozempic, and Rybelsus are distinct brand-name products with different routes, doses, and different FDA-approved indications. Insurance formularies treat them differently. Prior-authorization requirements differ. Even prescribers conflate them — in Cigna's CNF 360 GLP-1 prior-authorization policy, for example, “Rybelsus does NOT satisfy the step” when the policy requires a non-Rybelsus oral antidiabetic in the 130-day lookback (see our Cigna GLP-1 prior-authorization guide ). The brand / molecule / indication confusion has downstream cost and access consequences.

The cleanest mental model:

• Want oral semaglutide for type 2 diabetes? That is Rybelsus. FDA-approved 2019. Strict food restriction. Strengths 3 / 7 / 14 mg (plus 25 mg per recent label expansion).
• Want oral semaglutide for weight management? As of a 2026 label update, Wegovy tablets are FDA-approved for exactly that (cardiovascular risk reduction or weight reduction in adults). Rybelsus remains type-2-diabetes-only; off-label Rybelsus prescribing for weight loss still happens but is not its labeled population.
• Want an FDA-approved oral GLP-1 for weight management? That is Foundayo. FDA-approved April 2026. No food restriction. Six dose strengths. ATTAIN-1 anchor: −11.1% at 17.2 mg over 72 weeks.
• Want an injectable GLP-1 for weight management? That is Wegovy (semaglutide), Zepbound (tirzepatide), or Saxenda (liraglutide). Larger top-line efficacy than any oral, but injection-required.

Cost and channels

Anchor cash-pay prices verified to the WLR pricing dataset, July 2026:

• Foundayo (LillyDirect / Amazon Pharmacy): $149/month cash-pay. With Lilly's commercial savings card, eligible commercially insured patients can pay as little as $25/month.
• Rybelsus: Cash-pay price varies by channel; promotional pricing of $149/month has appeared in some channels tied to Rybelsus inventory under NovoCare/Novo Nordisk programs. Insurance coverage is structured around the T2D indication; weight-management off-label use is typically not covered.
• High-dose oral semaglutide for weight management: Wegovy tablets, FDA-approved in 2026 (OASIS-4), 25 mg once-daily maintenance dose.

Both FDA-approved oral GLP-1s are room-temperature stable — no refrigerator, no needles, no sharps container. That is the practical reason patients seek them out, even when the weight-loss ceiling is lower than the injectables. For the full cash-pay channel walkthrough across every GLP-1, see our Wegovy / GLP-1 cash-pay coupon channel guide and the live GLP-1 compounded pricing index .

Bottom line

Three oral GLP-1 stories matter in 2026 — and, as of a June 2026 label update, all three are now FDA-approved. Rybelsus (oral semaglutide, 2019, T2D-only) is the oldest option, with the strictest food restriction in the GLP-1 class — take at least 30 minutes before the first food, beverage, or other oral medications, with no more than 4 ounces of plain water — and a top labeled dose (14 mg, with 25 mg per label expansion) that produces modest weight loss as a secondary effect in T2D trials, NOT a labeled weight-management outcome. Foundayo (oral orforglipron, April 2026, weight-management-indicated) is a non-peptide small molecule with no food restrictions, six dose strengths from 0.8 mg to 17.2 mg, ATTAIN-1 −11.1% body weight at the top dose over 72 weeks. Wegovy tablets (high-dose oral semaglutide, added to the Wegovy label in 2026) are approved for cardiovascular risk reduction or weight reduction in adults — 1.5/4/9/25 mg once daily, OASIS-4 −13.6% at the 25 mg maintenance dose over 64 weeks, the largest FDA-approved oral GLP-1 weight-loss claim on record. Cross-trial comparison (with the usual caveats about differing populations and durations) now ranks the Wegovy tablet ahead of Foundayo for weight loss, both well ahead of Rybelsus — BUT injectable Wegovy 2.4 mg (~−14.9% STEP-1) and Zepbound 15 mg (~−20.9% SURMOUNT-1) still produce more top-line weight loss than any oral GLP-1. Choosing between them is a prescriber conversation anchored to indication, food-restriction tolerance, GI tolerability, target weight loss, and access channel.

Further reading

• Wegovy vs Foundayo matchup
• Top semaglutide weight-loss studies (curated PubMed reading list)
• Foundayo vs Rybelsus matchup
• Top oral-GLP-1 questions on Reddit, answered
• PIONEER 6 trial deep-dive (oral semaglutide cardiovascular outcomes)